Vimseltinib
Brand names: Romvimza · Active ingredient: Vimseltinib
In short: ROMVIMZA is indicated for treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity.
What is Vimseltinib used for?
ROMVIMZA is indicated for treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity.
Vimseltinib dosage
The recommended dosage of ROMVIMZA is 30 mg orally taken twice weekly, with a minimum of 72 hours between doses, as directed on the blister package . Instruct patients to follow the schedule on the blister package and to take ROMVIMZA on the same days each week.
ROMVIMZA may be taken with or without food.
Swallow ROMVIMZA capsules whole. Do not open, break, or chew the capsules.
If a dose is missed by 48 hours or less, take the missed dose as soon as possible and take the next dose on its regularly scheduled day. If a dose is missed by more than 48 hours, skip the missed dose, and take the next dose on its regularly scheduled day.
If vomiting occurs within 30 minutes of taking a dose, repeat that dose. Otherwise, take the next dose on its regularly scheduled day.
The recommended dose reductions for adverse reactions are provided in Table 1.
Dose Reduction | Twice Weekly Dose
First | 20 mg
Second | 14 mg
Permanently discontinue ROMVIMZA in patients who are unable to tolerate 14 mg orally twice weekly.
The recommended dosage modifications for hepatotoxicity are summarized in Table 2.
Hepatotoxicity Severity | ROMVIMZA Dosage Modifications
ALT = alanine aminotransferase; ALP = alkaline phosphatase; AST = aspartate aminotransferase; INR = International normalized ratio; ULN = upper limit of normal
AST and/or ALT increases >3–5 times ULN and total bilirubin increases up to 2 times ULN | Withhold ROMVIMZA until AST and ALT resolve to baseline or ≤3 times ULN, and bilirubin resolves to baseline.Resume at the next lower dose level once Hy's law has been definitively ruled out.Permanently discontinue if adverse reaction does not resolve within 4 weeks.
OR
Total bilirubin increases up to 2 times ULN
AST and/or ALT increases >3–5 times ULN, and total bilirubin increases >2 times ULN or INR >1.5 and ALP <2 times ULN | Withhold ROMVIMZA until AST and ALT resolve to baseline or ≤3 times ULN, and bilirubin resolves to baseline.Resume at the next lower dose level once Hy's law has been definitively ruled out.Permanently discontinue if adverse reaction does not resolve within 4 weeks.
OR
Total bilirubin increases >2 times ULN
AST and/or ALT increases >5–8 times ULN, and total bilirubin ≤ULN and without clinical symptoms | Withhold ROMVIMZA until AST and ALT resolve to ≤3 times ULN or baseline.
Resume at the next lower dose level.Permanently discontinue if adverse reaction does not resolve within 4 weeks.
AST and/or ALT increases >5-8 times ULN and total bilirubin increase >ULN, or INR >1.5, or ALP >2 times ULN | Permanently discontinue ROMVIMZA.
AST and/or ALT increases >8 times ULN | Permanently discontinue ROMVIMZA.
Avoid concomitant use of ROMVIMZA with P-gp substrates. …
How to take Vimseltinib — instructions & advice from the label
Advise the patient to read the FDA approved patient labeling (Medication Guide).
Hepatotoxicity
Advise patients there may be a potential risk of hepatotoxicity and that they will need to undergo laboratory tests to monitor liver function and to immediately report any signs or symptoms of severe liver injury to their healthcare provider .
Embryo-Fetal Toxicity
Advise pregnant women and females of reproductive potential of the potential risk to the fetus. Advise females of reproductive potential to inform their healthcare provider of a known or suspected pregnancy .
Advise females of reproductive potential to avoid pregnancy and to use effective contraception during treatment with ROMVIMZA and for 1 month after the last dose .
Advise males with female partners of reproductive potential to use effective contraception during treatment and for 1 month after the last dose of ROMVIMZA .
Lactation
Advise females not to breastfeed during treatment with ROMVIMZA and for 1 month after the final dose .
Infertility
Advise patients that ROMVIMZA may impair fertility .
Allergic Reactions to FD&C Yellow No. 5 (Tartrazine) and No. …
Warnings & precautions
Do not take this medicine if: None.
Cases of serious and fatal liver injury have occurred with the use of another kinase inhibitor that targets CSF1R . Serious and fatal liver injury have not been observed with ROMVIMZA.
Across clinical trials in 253 patients treated with ROMVIMZA, 2% had Grade 3 increased AST, and 1% had Grade 3 increased ALT. Dose interruptions occurred in 2% of patients and dose reductions occurred in 1% of patients due to AST/ALT increase. One patient discontinued therapy due to Grade 3 AST increased.
Avoid ROMVIMZA in patients with pre-existing increased serum transaminases; total bilirubin or direct bilirubin (>ULN); or active liver or biliary tract disease, including ALP. Monitor liver tests, including AST, ALT, total bilirubin, direct bilirubin, ALP and gamma-glutamyl transferase (GGT), prior to initiation of ROMVIMZA, twice a month for the first two months and once every 3 months for the first year of therapy and as clinically indicated thereafter. Withhold and reduce the dose, or permanently discontinue ROMVIMZA based on the severity of the hepatotoxicity .
Based on data from animal studies and its mechanism of action, ROMVIMZA can cause fetal harm when administered to pregnant women. In female rats administered vimseltinib, fetal structural abnormalities occurred at exposures that were at least 3 times the recommended dose based on area under the curve (AUC). Advise pregnant women on the potential risk to the fetus.
Advise females of reproductive potential and males with female partners of reproductive potential to use effective contraception during treatment with ROMVIMZA and for 1 month after the last dose .
ROMVIMZA 20 mg capsule contains FD&C Yellow No. 5 (tartrazine) which may cause allergic reactions (including bronchial asthma) in certain susceptible patients. Although the overall incidence of FD&C Yellow No. …
Vimseltinib side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
Hepatotoxicity
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The pooled safety population described in the Warnings and Precautions reflects exposure to ROMVIMZA in 83 patients with TGCT enrolled in the double-blind portion and in 35 patients with TGCT in the open-label portion who crossed over to ROMVIMZA in MOTION, and in 135 patients with TGCT or solid tumors in other clinical trials.
The safety of ROMVIMZA was evaluated in 83 adult patients with TGCT in MOTION . MOTION excluded patients with bilirubin, AST, or ALT >ULN. All patients received ROMVIMZA twice weekly until disease progression or unacceptable toxicity. Among these patients, 82% were exposed for 6 months or longer and 30% were exposed for greater than one year.
Serious adverse reactions occurred in 2.4% of patients who received ROMVIMZA. Serious adverse reactions in ≥1% included subcutaneous abscess (1.2%) and cellulitis (1.2%).
Permanent discontinuation due to an adverse reaction occurred in 4.8% of patients who received ROMVIMZA. Adverse reactions leading to permanent discontinuation in one patient each included periorbital edema, neuropathy, rash, and hypertension. …
Drug interactions
Table 5 describes drug interactions where concomitant use with ROMVIMZA affects another drug.
P-glycoprotein (P-gp) substrates
Prevention or Management | Avoid concomitant use with P-gp substrates while taking ROMVIMZA.If concomitant use cannot be avoided, take ROMVIMZA at least 4 hours prior to P-gp substrates unless otherwise recommended in the substrate Prescribing Information.
Mechanism and Clinical Effect(s) | This recommendation is based upon a mechanistic understanding of vimseltinib pharmacokinetics and it being a P-gp inhibitor in vitro . Concomitant use of ROMVIMZA with P-gp substrates may increase exposure of these substrates; however, this has not been studied clinically.
Breast Cancer Resistance Protein (BCRP) substrates
Prevention or Management | Avoid concomitant use with BCRP substrates while taking ROMVIMZA.Refer to the Prescribing Information of the BCRP substrate for dose modifications if concomitant use cannot be avoided.
Mechanism and Clinical Effect(s) | This recommendation is based upon a mechanistic understanding of vimseltinib pharmacokinetics and it being a BCRP inhibitor in vitro . Concomitant use of ROMVIMZA with BCRP substrates may increase exposure of these substrates; however, this has not been studied clinically. …
About this medicine
Vimseltinib is a kinase inhibitor. The chemical name of vimseltinib dihydrate is 3-methyl-5-[6-methyl-5-[2-(1-methylpyrazol-4-yl)pyridin-4-yl]oxypyridin-2-yl]-2-(propan-2-ylamino)pyrimidin-4-one, dihydrate.
Vimseltinib is a white to off-white crystalline solid. Vimseltinib is a weak base, very slightly soluble in water. The molecular formula for vimseltinib dihydrate is C23H25N7O2 • 2 H2O, and the molecular weight is 467.52 g/mol. The chemical structure is:
ROMVIMZA (vimseltinib) capsules are supplied as printed hard gelatin capsules containing 14 mg, 20 mg, or 30 mg of vimseltinib (equivalent to 15.18 mg, 21.68 mg, or 32.52 mg of vimseltinib dihydrate, respectively). The capsule contains the following inactive ingredients: crospovidone, lactose monohydrate, and magnesium stearate. The capsule shell contains Brilliant Blue FCF (30 mg strength), erythrosine (30 mg strength), gelatin, Sunset Yellow FCF (14 mg and 20 mg strengths), tartrazine (20 mg), and titanium dioxide.
How it works: Vimseltinib is a kinase inhibitor that inhibits colony-stimulating factor 1 receptor (CSF1R). …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID f73c7a62-9601-4df0-810f-100f515d79ea. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate